IDT Enters Clinical Diagnostics with New NGS Oncology Tests

BOULDER, CO – March 23, 2026 – Global genomics leader Integrated DNA Technologies (IDT) has officially entered the regulated clinical diagnostics market, launching its first in vitro diagnostic (IVD) offerings for next-generation sequencing (NGS). The introduction of the Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx assays in the United States and select European countries marks a significant strategic pivot for the company, moving it from a trusted provider of research tools to a direct player in patient diagnostics.

This move positions IDT to address a critical gap in the rapidly growing precision oncology sector, which is projected to expand from approximately $115 billion in 2024 to over $250 billion by 2034. The new IVD-grade solutions are designed to bring a higher level of standardization, reliability, and regulatory assurance to molecular pathology labs on the front lines of cancer care.

Addressing a Critical Need in Oncology Diagnostics

For years, clinical laboratories have navigated a complex landscape of lab-developed tests (LDTs) and research-use-only (RUO) products to perform genomic profiling of tumors. While powerful, these approaches often lack the standardization and regulatory oversight of IVDs, creating challenges in consistency and cross-institutional comparisons. IDT’s launch directly confronts this issue by providing a complete, out-of-the-box solution designed for clinical use.

“At IDT, we believe that precision diagnostics should be as reliable as they are innovative,” said Ajay Gannerkote, president of IDT, in a statement. “This launch reflects our commitment to supporting clinical labs with trusted solutions that combine innovative technology, ease-of-use, and regulatory assurance, so clinicians can focus on their mission-critical work to find the right answers across the expanding biomarker landscape.”

The new kits are engineered for efficiency and simplicity in a busy lab environment. They include color-coded, robot-friendly reagents and magnetic cleanup beads, and feature a workflow where key steps can run in parallel. This design reduces hands-on time and streamlines the complex process of library preparation for NGS, accelerating the path from a patient's sample to an actionable diagnostic result.

The Technology Behind the Leap: Anchored Multiplex PCR

The foundation of IDT’s new diagnostic assays is its proprietary Anchored Multiplex PCR (AMP™) chemistry. This technology is a key differentiator in the crowded NGS market and is particularly well-suited for the unique challenges of oncology diagnostics. Unlike some methods that require two gene-specific primers to amplify a target, AMP uses one gene-specific primer and one universal primer. This 'anchored' approach allows the system to detect not only known genetic variants and gene fusions but also previously undiscovered novel fusions—a critical capability given the chaotic and unpredictable nature of cancer genomes.

Furthermore, AMP chemistry incorporates unique molecular barcodes (MBCs) that tag each individual nucleic acid molecule at the beginning of the process. During data analysis, these barcodes allow the system to filter out errors and duplicate reads introduced during PCR amplification. The result is a highly accurate and quantitative measurement of the genetic variants present in the tumor, even at low frequencies.

This technical sophistication makes the technology exceptionally robust for use with challenging clinical samples. Tumor biopsies are often small and yield low-quality or degraded DNA and RNA, particularly when preserved as formalin-fixed, paraffin-embedded (FFPE) tissue. IDT's AMP chemistry is optimized to perform reliably with these low-input samples, maximizing the chances of obtaining a successful result from precious patient material.

Navigating a Competitive and Regulated Landscape

IDT enters an oncology NGS IVD market dominated by established giants like Illumina, with its FDA-approved TruSight Oncology Comprehensive (TSO Comprehensive) kits, and Thermo Fisher Scientific, with its Oncomine Dx test portfolio. These companies have already secured significant market share and established partnerships with pharmaceutical companies to develop companion diagnostics.

However, IDT’s strategy appears focused on carving out a niche by emphasizing workflow efficiency, regulatory compliance, and the unique capabilities of its AMP technology. The launch is also timely, as it aligns with a major industry trend driven by stricter regulatory frameworks. In Europe, the stringent In Vitro Diagnostic Regulation (IVDR) has raised the bar for all diagnostic tests, pushing manufacturers toward more robust, clinically validated solutions. In the US, the FDA has created a more defined pathway for NGS-based tumor profiling tests as Class II medical devices. By launching FDA-registered and CE-IVD compliant products, IDT is directly responding to this demand for greater regulatory certainty.

A Strategic Move within the Danaher Ecosystem

This expansion into clinical diagnostics is not an isolated venture but a calculated move that aligns with the broader strategy of IDT’s parent company, Danaher Corporation. Over the past two decades, Danaher has transformed itself from an industrial manufacturer into a global powerhouse in life sciences and diagnostics, driven by strategic acquisitions and a relentless focus on innovation.

Danaher's portfolio includes a suite of companies that support the entire cancer patient journey, from Leica Biosystems' pathology imaging to Cepheid's molecular diagnostics. IDT’s entry into oncology IVDs fits seamlessly into this ecosystem, strengthening Danaher's position in the high-growth molecular diagnostics segment. The move creates powerful synergies, offering the potential for integrated diagnostic workflows that combine NGS with other technologies across Danaher's operating companies.

As part of its long-term vision, IDT has signaled that this is only the beginning of its foray into the IVD space. The company plans to continue expanding its Archer IVD portfolio, leveraging the foundational AMP technology to provide open access to a full range of NGS assay capabilities for detecting complex variants and fusions, ultimately aiming to make precision medicine a routine reality for more patients.